DK1025227T3 - Humane TOLL-homologer - Google Patents

Humane TOLL-homologer

Info

Publication number
DK1025227T3
DK1025227T3 DK98953294T DK98953294T DK1025227T3 DK 1025227 T3 DK1025227 T3 DK 1025227T3 DK 98953294 T DK98953294 T DK 98953294T DK 98953294 T DK98953294 T DK 98953294T DK 1025227 T3 DK1025227 T3 DK 1025227T3
Authority
DK
Denmark
Prior art keywords
human toll
pro286
pro285
pro358
proteins
Prior art date
Application number
DK98953294T
Other languages
Danish (da)
English (en)
Inventor
Audrey Goddard
Paul J Godowski
Austin L Gurney
Melanie R Mark
Ruey-Bing Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27535565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1025227(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1025227T3 publication Critical patent/DK1025227T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
DK98953294T 1997-10-17 1998-10-07 Humane TOLL-homologer DK1025227T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6225097P 1997-10-17 1997-10-17
US6531197P 1997-11-13 1997-11-13
US8332298P 1998-04-28 1998-04-28
US10541398A 1998-06-26 1998-06-26
US9086398P 1998-06-26 1998-06-26

Publications (1)

Publication Number Publication Date
DK1025227T3 true DK1025227T3 (da) 2006-05-01

Family

ID=27535565

Family Applications (3)

Application Number Title Priority Date Filing Date
DK98953294T DK1025227T3 (da) 1997-10-17 1998-10-07 Humane TOLL-homologer
DK05023238T DK1650219T3 (da) 1997-10-17 1998-10-07 Humane TOLL-homologer
DK07020354.2T DK1887014T3 (da) 1997-10-17 1998-10-07 Humane Toll-homologer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK05023238T DK1650219T3 (da) 1997-10-17 1998-10-07 Humane TOLL-homologer
DK07020354.2T DK1887014T3 (da) 1997-10-17 1998-10-07 Humane Toll-homologer

Country Status (11)

Country Link
EP (3) EP1650219B1 (ja)
JP (3) JP4319348B2 (ja)
AT (3) ATE314471T1 (ja)
AU (1) AU1070399A (ja)
CA (1) CA2305385C (ja)
DE (3) DE69838888T2 (ja)
DK (3) DK1025227T3 (ja)
ES (2) ES2343210T3 (ja)
IL (4) IL135345A0 (ja)
PT (2) PT1650219E (ja)
WO (1) WO1999020756A2 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696327B1 (en) 1997-10-17 2010-04-13 Genentech, Inc. Antibodies to human Toll homologues
AU2001264889B2 (en) * 1997-05-07 2006-06-29 Schering Corporation Human receptor proteins; related reagents and methods
CN1225555C (zh) * 1997-05-07 2005-11-02 先灵公司 人Toll样受体蛋白、相关试剂和方法
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
HUP0302240A2 (hu) * 2000-05-25 2003-10-28 Schering Corp. Humán receptorfehérjék, ezekkel kapcsolatos reagensek és eljárások
AU2001291096A1 (en) 2000-09-15 2002-03-26 Coley Pharmaceutical Gmbh Process for high throughput screening of CpG-based immuno-agonist/antagonist
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1293566A1 (en) * 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. A soluble toll-like receptor
KR20040099418A (ko) * 2002-04-08 2004-11-26 다케다 야쿠힌 고교 가부시키가이샤 중증 패혈증 예방 치료제
DE60336341D1 (de) 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
EP1575978A4 (en) 2002-11-12 2006-04-19 Becton Dickinson Co DIAGNOSIS OF SEPSIS OR SIRS USING BIOLOGICAL MARKERS PROFILES
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
EP1631687A2 (en) * 2003-04-22 2006-03-08 Coley Pharmaceutical GmbH Methods and products for identification and assessment of tlr ligands
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US8163506B2 (en) 2003-06-17 2012-04-24 Meiji Co., Ltd. Use of toll-like receptor-expressing cells
JP4562123B2 (ja) * 2003-06-17 2010-10-13 明治乳業株式会社 Ｔｏｌｌ様レセプター強制発現細胞の利用
US7288250B2 (en) 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
EP1750757B1 (en) 2004-05-18 2013-03-13 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
JP2008500064A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用
US7767395B2 (en) 2005-04-15 2010-08-03 Becton, Dickinson And Company Diagnosis of sepsis
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
ES2435775T3 (es) 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
AU2007297565A1 (en) * 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ES2473610T3 (es) 2006-10-10 2014-07-07 Acorda Therapeutics, Inc. Composiciones y métodos de uso de mutantes de condroitinasa ABCI
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
TWI481401B (zh) 2010-01-27 2015-04-21 Takeda Pharmaceutical 藥劑
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CN1225555C (zh) * 1997-05-07 2005-11-02 先灵公司 人Toll样受体蛋白、相关试剂和方法
ES2263865T3 (es) * 1998-03-25 2006-12-16 Genentech, Inc. Homologo humano de neurotrimina.

Also Published As

Publication number Publication date
CA2305385C (en) 2013-05-21
EP1887014B1 (en) 2010-04-07
EP1025227B1 (en) 2005-12-28
DE69838888T2 (de) 2008-12-11
ATE314471T1 (de) 2006-01-15
CA2305385A1 (en) 1999-04-29
DE69833014D1 (de) 2006-02-02
JP4319348B2 (ja) 2009-08-26
IL180967A (en) 2012-09-24
PT1650219E (pt) 2008-03-31
JP5425244B2 (ja) 2014-02-26
IL135345A (en) 2007-06-03
ATE381574T1 (de) 2008-01-15
EP1650219B1 (en) 2007-12-19
JP2012105662A (ja) 2012-06-07
EP1025227A2 (en) 2000-08-09
DK1650219T3 (da) 2008-05-05
EP1650219A1 (en) 2006-04-26
WO1999020756A3 (en) 1999-09-10
DE69838888D1 (de) 2008-01-31
IL221367A (en) 2015-06-30
PT1887014E (pt) 2010-07-05
EP1887014A1 (en) 2008-02-13
ES2298905T3 (es) 2008-05-16
JP5027105B2 (ja) 2012-09-19
DE69841607D1 (de) 2010-05-20
ES2343210T3 (es) 2010-07-26
IL135345A0 (en) 2001-05-20
ATE463502T1 (de) 2010-04-15
JP2009131265A (ja) 2009-06-18
JP2002526028A (ja) 2002-08-20
DE69833014T2 (de) 2006-08-10
DK1887014T3 (da) 2010-08-02
WO1999020756A2 (en) 1999-04-29
AU1070399A (en) 1999-05-10
IL180967A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
DK1650219T3 (da) Humane TOLL-homologer
ATE329028T1 (de) Nl3 tie rezeptortyrosinekinase ligandhomologe
IL131016A0 (en) Selection of proteins using rna-protein fusions
DE69813158T2 (de) Assays zur Bestimmung von Proteinfragmenten in biologischen Medien
CY1116863T1 (el) Πρωτεϊνη δεσμευσης υποδοχεα nogo
ATE394484T1 (de) Smad 6 und dessen anwendungen
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ES2178203T3 (es) Metodos y reactivos para modular la apoptosis.
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE59712604D1 (de) Mittel zur identifizierung und therapie metastasierender tumore
WO2001081623A3 (de) Neuronal exprimiertes protein mit apoptoseaktivität und seine verwendung